{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:24:37Z","timestamp":1780428277435,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>There are numerous curative treatment possibilities for prostate cancer. In patients who have undergone rectal extirpation for rectal cancer treatment, curative options are limited due to anatomic changes and previous irradiation of the pelvis. In this analysis, we validate the feasibility of CT-guided transperineal interstitial brachytherapy for this specific scenario.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>We analyzed the treatment procedures and outcomes of 5\u00a0patients with metachronic nonmetastatic prostate cancer. Ultrasound-guided brachytherapy was not possible in any of the patients. Of these 5\u00a0patients, 3\u00a0were treated for prostate cancer using temporary brachytherapy with Ir-192 only, and 2\u00a0were treated with external-beam radiation therapy and temporary brachytherapy as a\u00a0boost. CT-guided brachytherapy was performed in all patients. We analyzed the feasibility, efficacy, treatment-related toxicity, and quality of life (EORTC-30, IEFF, IPSS, and ICIQ questionnaires) of the treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Median follow-up was 35\u00a0months. Two out of five patients received boost irradiation (HDR 2\u202f\u00d7\u20099\u00a0Gy, PDR 30\u202fGy). Three out of five patients were treated with PDR brachytherapy in two sessions up to a\u00a0total dose of 60\u202fGy. Dosimetric parameters were documented as median values as follows: V100 94.7% (94.5\u201398.4%), D2<jats:sub>bladder<\/jats:sub> 64.3% (50.9\u201378.3%), D10<jats:sub>urethra<\/jats:sub> 131.05% (123.2%\u2013141.2%), and D30<jats:sub>urethra<\/jats:sub> 122.45% (116.2%\u2013129.5%). At the time of analysis, no biochemical recurrence had been documented. Furthermore, neither early nor late side effects exceeding CTCAE grade\u00a02 were documented.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>CT-guided transperineal brachytherapy of the prostate in patients with previous rectal surgery and radiation therapy is safe and represents a\u00a0possible curative treatment option. Brachytherapy can be considered for patients with metachronic prostate cancer in this specific scenario, albeit preferably in experienced high-volume centers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00066-024-02266-y","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T17:01:55Z","timestamp":1722618115000},"page":"20-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Protocol-based CT-guided brachytherapy for patients with prostate cancer and previous rectal extirpation\u2014a\u00a0curative approach"],"prefix":"10.1007","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0353-6283","authenticated-orcid":false,"given":"Philipp","family":"Schubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vratislav","family":"Strnad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wei\u00dfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kreppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Karius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Merten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"issue":"40","key":"2266_CR1","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.3748\/wjg.v24.i40.4586","volume":"24","author":"TH Wang","year":"2018","unstructured":"Wang\u00a0TH, Liu\u00a0CJ, Chao\u00a0TF, Chen\u00a0TJ, Hu\u00a0YW (2018) Second primary malignancy risk after radiotherapy in rectal cancer survivors. World J Gastroenterol 24(40):4586\u20134595","journal-title":"World J Gastroenterol"},{"issue":"17","key":"2266_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy\u00a0FC, Donovan\u00a0JL, Lane\u00a0JA, Metcalfe\u00a0C, Davis\u00a0M, Turner\u00a0EL et\u00a0al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N\u00a0Engl J Med 388(17):1547\u20131558","journal-title":"N Engl J Med"},{"issue":"6","key":"2266_CR3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s00066-023-02060-2","volume":"199","author":"J Rosenbrock","year":"2023","unstructured":"Rosenbrock\u00a0J, Baues\u00a0C, Kreis\u00a0M, Fouassi\u00a0R, Celik\u00a0E, Paffenholz\u00a0P et\u00a0al (2023) Toxicity of dose-escalated radiotherapy up to 84\u202fGy for prostate cancer. Strahlenther Onkol 199(6):574\u2013584","journal-title":"Strahlenther Onkol"},{"key":"2266_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fonc.2019.00529","volume":"9","author":"SY Chung","year":"2019","unstructured":"Chung\u00a0SY, Koom\u00a0WS, Keum\u00a0KC, Chang\u00a0JS, Shin\u00a0SJ, Ahn\u00a0JB et\u00a0al (2019) Treatment outcomes of re-irradiation in Locoregionally recurrent rectal cancer and clinical significance of proper patient selection. Front Oncol 9:529","journal-title":"Front Oncol"},{"issue":"1","key":"2266_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","volume":"109","author":"WA Hall","year":"2021","unstructured":"Hall\u00a0WA, Paulson\u00a0E, Davis\u00a0BJ, Spratt\u00a0DE, Morgan\u00a0TM, Dearnaley\u00a0D et\u00a0al (2021) NRG oncology updated international consensus Atlas on pelvic lymph node volumes for intact and postoperative prostate cancer. Int J Radiat Oncol Biol Phys 109(1):174\u2013185","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2266_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.radonc.2012.07.003","volume":"104","author":"S Lettmaier","year":"2012","unstructured":"Lettmaier\u00a0S, Lotter\u00a0M, Kreppner\u00a0S, Strnad\u00a0A, Fietkau\u00a0R, Strnad\u00a0V (2012) Long term results of a\u00a0prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer. Radiother Oncol 104(2):181\u2013186","journal-title":"Radiother Oncol"},{"issue":"15","key":"2266_CR7","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1200\/JCO.2016.72.0466","volume":"35","author":"J Chin","year":"2017","unstructured":"Chin\u00a0J, Rumble\u00a0RB, Kollmeier\u00a0M, Heath\u00a0E, Efstathiou\u00a0J, Dorff\u00a0T et\u00a0al (2017) Brachytherapy for patients with prostate cancer: American society of clinical oncology\/cancer care ontario joint guideline update. J\u00a0Clin Oncol 35(15):1737\u20131743","journal-title":"J Clin Oncol"},{"key":"2266_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","volume":"167","author":"A Henry","year":"2022","unstructured":"Henry\u00a0A, Pieters\u00a0BR, Siebert\u00a0AF, Hoskin\u00a0P, UgoGEwebtEAo (2022) GEC-ESTRO ACROP prostate brachytherapy guidelines. Radiother Oncol 167:244\u2013251","journal-title":"Radiother Oncol"},{"issue":"1","key":"2266_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brachy.2016.09.006","volume":"16","author":"DE Spratt","year":"2017","unstructured":"Spratt\u00a0DE, Soni\u00a0PD, McLaughlin\u00a0PW, Merrick\u00a0GS, Stock\u00a0RG, Blasko\u00a0JC, American Brachytherapy Society Task Group Report et\u00a0al (2017) Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy 16(1):1\u201312","journal-title":"Brachytherapy"},{"issue":"2","key":"2266_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet\u00a0N, van den Bergh\u00a0RCN, Briers\u00a0E, Van den Broeck\u00a0T, Cumberbatch\u00a0MG, De Santis\u00a0M et\u00a0al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer \u2013 2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243\u2013262","journal-title":"Eur Urol"},{"key":"2266_CR11","doi-asserted-by":"crossref","unstructured":"Moll M, Nechvile E, Kirisits C, Komina O, Pajer T, Kohl B et\u00a0al (2024) Radiotherapy in localized prostate cancer: a\u00a0multicenter analysis evaluating tumor control and late toxicity after brachytherapy and external beam radiotherapy in 1293 patients. Strahlenther Onkol","DOI":"10.1007\/s00066-024-02222-w"},{"key":"2266_CR12","doi-asserted-by":"crossref","unstructured":"Shen B, Liu J, Wu D, Guo J (2024) Evaluation of the safety and efficacy of high-dose rate brachytherapy for radiorecurrent prostate cancer: a\u00a0systematic review and meta-analysis. Strahlenther Onkol","DOI":"10.1007\/s00066-024-02205-x"},{"issue":"6","key":"2266_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","volume":"8","author":"DP Dearnaley","year":"2007","unstructured":"Dearnaley\u00a0DP, Sydes\u00a0MR, Graham\u00a0JD, Aird\u00a0EG, Bottomley\u00a0D, Cowan\u00a0RA et\u00a0al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475\u2013487","journal-title":"Lancet Oncol"},{"issue":"7","key":"2266_CR14","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","volume":"28","author":"AL Zietman","year":"2010","unstructured":"Zietman\u00a0AL, Bae\u00a0K, Slater\u00a0JD, Shipley\u00a0WU, Efstathiou\u00a0JA, Coen\u00a0JJ et\u00a0al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/american college of radiology 95\u201309. J\u00a0Clin Oncol 28(7):1106\u20131111","journal-title":"J Clin Oncol"},{"issue":"6","key":"2266_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.prro.2021.04.007","volume":"11","author":"SY Wu","year":"2021","unstructured":"Wu\u00a0SY, Wong\u00a0AC, Shinohara\u00a0K, Roach\u00a0M 3rd, Cunha\u00a0JAM, Valdes\u00a0G et\u00a0al (2021) Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation. Pract Radiat Oncol 11(6):515\u2013526","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"2266_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","volume":"80","author":"LF Valle","year":"2021","unstructured":"Valle\u00a0LF, Lehrer\u00a0EJ, Markovic\u00a0D, Elashoff\u00a0D, Levin-Epstein\u00a0R, Karnes\u00a0RJ et\u00a0al (2021) A\u00a0systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol 80(3):280\u2013292","journal-title":"Eur Urol"},{"key":"2266_CR17","doi-asserted-by":"crossref","unstructured":"Drobner J, Kaldany A, Shah MS, Ghodoussipour S (2023) The Role of Salvage Radical Prostatectomy in Patients with Radiation-Resistant Prostate Cancer. Cancers (basel) 15(14)","DOI":"10.3390\/cancers15143734"},{"issue":"1","key":"2266_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.brachy.2016.06.003","volume":"16","author":"NH Bittner","year":"2017","unstructured":"Bittner\u00a0NH, Orio\u00a0PF 3rd, Merrick\u00a0GS, Prestidge\u00a0BR, Hartford\u00a0AC, Rosenthal\u00a0SA (2017) The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancer. Brachytherapy 16(1):59\u201367","journal-title":"Brachytherapy"},{"issue":"6","key":"2266_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/COC.0000000000000915","volume":"45","author":"NHJ Bittner","year":"2022","unstructured":"Bittner\u00a0NHJ, Cox\u00a0BW, Davis\u00a0B, King\u00a0M, Lawton\u00a0CAF, Merrick\u00a0GS et\u00a0al (2022) ACR-ABS-ASTRO practice parameter for transperineal permanent brachytherapy of prostate cancer. Am J Clin Oncol 45(6):249\u2013257","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"2266_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00066-014-0781-3","volume":"191","author":"F Collettini","year":"2015","unstructured":"Collettini\u00a0F, Schreiber\u00a0N, Schnapauff\u00a0D, Denecke\u00a0T, Wust\u00a0P, Schott\u00a0E et\u00a0al (2015) CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol 191(5):405\u2013412","journal-title":"Strahlenther Onkol"},{"issue":"11","key":"2266_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s00066-019-01501-1","volume":"195","author":"R Damm","year":"2019","unstructured":"Damm\u00a0R, Streitparth\u00a0T, Hass\u00a0P, Seidensticker\u00a0M, Heinze\u00a0C, Powerski\u00a0M et\u00a0al (2019) Prospective evaluation of CT-guided HDR brachytherapy as a\u00a0local ablative treatment for renal masses: a\u00a0single-arm pilot trial. Strahlenther Onkol 195(11):982\u2013990","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"2266_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/01.ju.0000146043.65229.9b","volume":"173","author":"PG Koutrouvelis","year":"2005","unstructured":"Koutrouvelis\u00a0PG, Theodorescu\u00a0D, Katz\u00a0S, Lailas\u00a0N, Hendricks\u00a0F (2005) Brachytherapy of prostate cancer after colectomy for colorectal cancer: pilot experience. J\u00a0Urol 173(1):82\u201385 (discussion 5\u20136)","journal-title":"J Urol"},{"issue":"4","key":"2266_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.brachy.2009.02.004","volume":"8","author":"S Jabbari","year":"2009","unstructured":"Jabbari\u00a0S, Hsu\u00a0IC, Kawakami\u00a0J, Weinberg\u00a0VK, Speight\u00a0JL, Gottschalk\u00a0AR et\u00a0al (2009) High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. Brachytherapy 8(4):339\u2013344","journal-title":"Brachytherapy"},{"key":"2266_CR24","doi-asserted-by":"crossref","unstructured":"Celentano G, Creta M, Napolitano L, Abate M, La Rocca R, Capece M et\u00a0al (2022) Prostate cancer diagnosis, treatment and outcomes in patients with previous or synchronous colorectal cancer: a\u00a0systematic review of published evidence. Diagnostics (Basel) 12(6)","DOI":"10.3390\/diagnostics12061475"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02266-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02266-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02266-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T10:54:34Z","timestamp":1737024874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02266-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2266"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02266-y","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"assertion":[{"value":"14 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.\u00a0Schubert, V.\u00a0Strnad, T.\u00a0Wei\u00dfmann, C.\u00a0Schweizer, M.\u00a0Lotter, S.\u00a0Kreppner, A.\u00a0Karius, R.\u00a0Fietkau, and R.\u00a0Merten declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}